p38α MAPK, initially discovered as a target for inhibition of proinflammatory cytokines, has been linked to
several CNS disorders in preclinical animal models of CNS diseases, including Alzheimer’s disease, Amyotrophic Lateral
Sclerosis (ALS), cerebral ischemia and neuropathic pain. Here we describe pharmacophore and similarity-based virtual
screenings of more than 18.3 million compounds based on correlation between the specific binding mode and activity of
different types of p38α MAPK inhibitors and present novel potential p38α MAPK inhibitors.